ArticleNeurology and therapy2026

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Piero Barbanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.